Clinical trialNCT02047214TerminatedPhase 2Interventional

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

SponsorCortice Biosciences, Inc.Enrollment17Glioblastoma Multiforme

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following prior radiation and temozolomide (TMZ) therapy and that has progressed following prior bevacizumab therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Camilo E. Fadul, M.D., F.A.A.N.
Dartmouth-Hitchcock Medical Center
Principal Investigator
clinicaltrials.gov ↗
David Schiff, M.D.
University of Virginia Health System
Principal Investigator
clinicaltrials.gov ↗
Jian Campian, M.D., Ph.D.
Washington University School of Medicine
Principal Investigator
clinicaltrials.gov ↗
Louis B. Nabors, III, M.D.
University of Alabama at Birmingham
Principal Investigator
clinicaltrials.gov ↗
Nimish Mohile, M.D.
University of Rochester
Principal Investigator
clinicaltrials.gov ↗
Pierre Giglio, M.D.
Ohio State University
Principal Investigator
clinicaltrials.gov ↗
Priya Kumthekar, M.D.
Northwestern University
Principal Investigator
clinicaltrials.gov ↗
Samuel A. Goldlust, M.D.
John Theurer Cancer Center at Hackensack University Medical Center
Principal Investigator
clinicaltrials.gov ↗
Sigmund Hsu, M.D.
Memorial Hermann Hospital
Principal Investigator
clinicaltrials.gov ↗
Solmaz Sahebjam, M.D.
H Lee Moffitt Cancer Center and Research Institute, Inc.
Principal Investigator
clinicaltrials.gov ↗
Tara L. Benkers, M.D.
Swedish Neuroscience Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
H Lee Moffitt Cancer Center and Research Institute, Inc.
Tampa, Florida, United States
Northwestern Medical Faculty Foundation
Chicago, Illinois, United States
Washington University, School of Medicine
St Louis, Missouri, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
University of Rochester Medical Center
Rochester, New York, United States
the Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Memorial Hermann Hospital
Houston, Texas, United States
University of Virginia Health System
Charlottesville, Virginia, United States
Swedish Neuroscience Institute
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bevacizumab →TPI-287

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2014
Primary completion: 31 Dec 2015
Completion: 31 Dec 2015
Last update posted: 31 Jan 2018
Registered enrollment: 17
Registry id: NCT02047214

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.